ASCO17: AstraZeneca's Lynparza stays step ahead of PARP rivals

Data showing a 42% risk reduction in disease worsening compared to chemo in breast cancer patients should help build Lynparza's profile outside of ovarian cancer. 

By Ned Pagliarulo • June 4, 2017

ASCO17: Incyte pads its IDO numbers

IDO inhibitors have been pegged as the next step in immuno-oncology combinations, but Incyte's rising market value prompts questions over what that's worth. 

By Ned Pagliarulo • June 3, 2017

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

ASCO17: Loxo shows promise of biomarker approach to cancer

Clinical data presented Saturday showed treatment with Loxo Oncology's larotrectinib shrank tumors in three-quarters of patients with a range of 17 different advanced cancers. 

By Ned Pagliarulo • June 3, 2017

Prescribed Reading: Combos to take center stage at ASCO

On the eve of ASCO, some question the validity of certain combination testing for oncology drugs, pointing to the increased number of combo trials taking place. 

By Lisa LaMotta • June 2, 2017

The perils of building clinical trials on a shaky foundation

With the odds stacked against clinical trial success, drug developers need all the tools in their arsenal to make sure they recruit patients quickly and design trials effectively. 

By Craig Morgan • June 1, 2017

Critical considerations for successful immunotherapy trials

Every cancer immunotherapy trial is different, but there are several best practices biopharmaceutical companies can follow to shorten the distance from lab to life.

June 1, 2017

Phase 3 success keeps Teva in migraine race

No headache for Teva as it announces positive trial results for its migraine drug, one of several new treatments nearing potential approval. 

By Suzanne Elvidge • June 1, 2017

Lilly's Cyramza scores in bladder cancer

The positive data could set the company up to compete with a range of checkpoint inhibitors in the indication.

By Lisa LaMotta • May 31, 2017

NLS touts Mazindol's efficacy as it takes on ADHD market

The clinical-stage pharma revealed that the majority of patients taking its ADHD drug in a Phase 2 trial had at least a 50% reduction in disease symptoms.

By Jacob Bell • May 31, 2017

Gilead tees up filing for HIV triple combo after Phase 3 wins

The biotech hopes the therapy, if approved, will accelerate the adoption of its portfolio of newer HIV treatments, which have become more important as HCV sales fall fast. 

By Ned Pagliarulo • May 30, 2017

Finding the other 90%: Attracting naïve patients to RA studies

There is significant research being targeted towards the treatment of rheumatoid arthritis (RA), but how can the industry attract more clinical trial participants?

May 30, 2017

Novo Nordisk seeks expanded label for Tresiba

The DEVOTE study showed non-inferiority in cardiovascular safety and improvement in hypoglycemia — but will this be enough for the FDA?

By Suzanne Elvidge • May 30, 2017

Industry Pulse: R&D spending in charts

Biopharmas are always on the hunt for ever-elusive innovations, but some are better at allocating investment than others. Here are five charts showing how the industry spends on R&D. 

By Ned Pagliarulo • May 30, 2017

Prescribed Reading: FDA on a roll, while pharma continues sell off

The regulatory agency continues its approval spree, just as big pharma sells off older assets in its ongoing restructuring. 

By Lisa LaMotta • May 26, 2017

Hopes are high for cannabinoid data in epilepsy

GW Pharmaceuticals' stock price spiked after it published epilepsy data, and submission for Epidiolex in the U.S. is now imminent.

By Suzanne Elvidge • May 26, 2017

Aerie shares rise on trial success for eye drug

The positive results could help Aerie make the jump from a clinical-stage company to a commercial one over the next two years.

By Ned Pagliarulo • May 25, 2017

Neurocrine's Tourette's trial gets a red light

Ingrezza failed to beat placebo in a Phase 2 trial, pushing its stock price down. 

By Suzanne Elvidge • May 24, 2017

Trial success buoys AstraZeneca's hopes for asthma biologic

Benralizumab is the most advanced example of AstraZeneca's push to expand its respiratory portfolio into biologics.

By Ned Pagliarulo • May 23, 2017

Celgene MS drug succeeds in second Phase 3 study

But the drug failed to beat out Biogen's Avonex in slowing disability progression, a missed opportunity to stand out in a crowded therapeutic class. 

By Ned Pagliarulo • May 22, 2017

La Jolla falls on mixed results for shock treatment

The drug met its primary endpoint, boding well for its chances with the FDA. But results were less promising on secondary measures of organ failure and mortality.  

By Suzanne Elvidge • May 22, 2017

Safety signal derails expected approval of Amgen bone drug

Amgen no longer expects to win U.S. approval this year for romosuzumab after reporting an imbalance of cardiovascular adverse events in a comparator study.

By Ned Pagliarulo • May 22, 2017

Prescribed Reading: ASCO dominates, Icahn BMS interest just a rumor

The abstracts have arrived! Carl Icahn's first quarter holdings are released and J&J gets a black box warning. 

By Lisa LaMotta • May 19, 2017

Albireo rises on Phase 3 plans for liver drug

Following discussions with the FDA and EMA, the Boston-based biotech plans to kick off its Phase 3 trial in the second half of this year. 

By Suzanne Elvidge • May 19, 2017

7 Areas to watch from the ASCO abstracts

With oncology's biggest meeting less than two weeks away, here are seven highlights from the recently released abstracts that are worth keeping an eye on. 

By Ned Pagliarulo • May 18, 2017

Shire's angioedema drug scores in Phase 3

Patients receiving a 300 mg dose of lanadelumab every other week had an 87% reduction in average number of hereditary angiodema attacks versus those on placebo.

By Jacob Bell • May 18, 2017